Germline Pathogenic Variants and Clinical Outcomes in Asian Patients With Breast Cancer
Open Access
- 10 February 2025
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 116 (4) , 1048-1058
Abstract
Despite the importance of genetic testing for risk assessment and treatment in breast cancer, the prognostic impact of germline pathogenic variants (PVs), especially in Asian populations, is unclear. We assessed the impact of germline PVs in patients with early‐stage breast cancer. This study included 7278 Japanese multihospital registry patients. PVs of ATM, BRCA1, BRCA2, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, STK11, and TP53 were evaluated. PV and non‐PV carriers were matched by age, histology, and stage. Associations between PVs and survival were assessed. The primary outcome was invasive disease‐free survival (IDFS). Secondary outcomes included relapse‐free survival (RFS), overall survival, and breast cancer‐specific survival. We identified 320 (4.4%) patients with BRCA1/2 PVs and 79 (1.1%) with PVs other than BRCA1/2 (non‐BRCA1/2). A total of 360 patients (BRCA1/2, n = 289; non‐BRCA1/2, n = 71) were matched to 720 noncarriers. Patients with BRCA1/2 PVs had significantly shorter 10‐year IDFS (adjusted hazard ratio (aHR) = 2.15; 95% confidence interval (CI), 1.61–2.86; p < 0.001); and RFS (aHR = 1.74; 95% CI, 1.25–2.44; p = 0.001) than noncarriers. Among patients with hormone receptor‐positive HER2‐negative breast cancer, BRCA1/2 PV carriers exhibited significantly shorter 10‐year IDFS than noncarriers, even those with stage I/II disease (total, aHR = 2.23; 95% CI, 1.55–3.23; p < 0.001, Stage I/II, aHR = 2.22; 95% CI, 1.43–3.44; p < 0.001). There was no significant difference in 10‐year IDFS between the non‐BRCA1/2 PV carrier and noncarrier groups (aHR = 1.40; 95% CI, 0.67–2.93; p = 0.37). Asian patients with breast cancer carrying germline BRCA1/2 PV, even those with a low recurrence risk, have significantly shorter 10‐year IDFS than noncarriers.Keywords
Funding Information
- Japan Society for the Promotion of Science (JP18K16292 20H03668 23H02955)
- Japan Agency for Medical Research and Development (JP15ck0106096 19cm0106605h0003 23ama2)
This publication has 31 references indexed in Scilit:
- Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancerAnnals of Oncology, 2022
- Insights Into Breast Cancer in the East vs the WestJAMA Oncology, 2019
- Risk Assessment, Genetic Counseling, and Genetic Testing forBRCA-Related CancerJAMA, 2019
- Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trialThe Lancet Oncology, 2018
- Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort studyThe Lancet Oncology, 2018
- Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation CarriersJAMA, 2017
- Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysisFamilial Cancer, 2015
- Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysisThe Lancet Oncology, 2015
- Breast cancerThe Lancet, 2005
- Age as a prognostic factor in breast cancer: Relationship to pathologic and biologic featuresInternational Journal of Cancer, 1995